Accurate urinary bladder cancer diagnosis by automated FTIR

Skip to Navigation

Blog Post

  • Published: Jan 21, 2014
  • Author: Steve Down
  • Channels: UV/Vis Spectroscopy / Chemometrics & Informatics / Proteomics / Base Peak / NMR Knowledge Base / X-ray Spectrometry / Raman / Infrared Spectroscopy / Atomic / MRI Spectroscopy

View comments on this post

A novel FTIR spectroscopic test for urinary bladder cancer developed by scientists in Germany has been improved to give a more accurate diagnosis, distinguishing patients from those with urinary tract infections. Writing in Journal of Biophotonics, Klaus Gewert and colleagues illustrated that a larger patient set and adjusted data measurement and processing techniques gave better results.

Blood plasma stabilised with citrate or EDTA, or serum, was collected from patients with different stages of urinary bladder cancer or other conditions such as urocystitis and urethral infection. Dried thin films of the biofluids were characterised by automated FTIR spectroscopy with a resolution of 4 cm–1, and discriminative patterns in the spectra were identified and validated. They led to a classification accuracy of 80%, with sensitivity and specificity of 78 and 81%, respectively.

Improved methods such as this will remove the need for repeated patient cytoscopy, an uncomfortable procedure, for patients with recurring bladder cancer. Being fully automated, the method provides the high throughput expected of screening labs. However, testing on even larger number of patients is required before the method can be integrated into clinical practice.


There are currently no comments on this post.

Comment Form

You have to log in to comment on this post.

Log in using the form at the top of the page or register here.

Social Links

Share This Links

Bookmark and Share


Suppliers Selection
Societies Selection

Banner Ad

Click here to see
all job opportunities

Copyright Information

Interested in separation science? Visit our sister site

Copyright © 2018 John Wiley & Sons, Inc. All Rights Reserved